ClinicalTrials.gg
CompletedNCT03257943Updated May 18, 2018

A Bioequivalence Study, Comparing Two Formulations of Ivermectin Lotion, 0.5%

A Phase 1 interventional study of Ivermectin Lotion, 0.5% and SKLICE (ivermectin) Lotion, 0.5% in Lice; Head Lice, sponsored by Taro Pharmaceuticals USA. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-05-18.

Sponsored by Taro Pharmaceuticals USA (part of Sun Pharmaceutical Industries Limited) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jun 2017, 9 years 4 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
413
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 25 studies in Lice Infestations with a site in United States — 1 open to participants now, 1 under way, none of them phase 3. Lice Infestations · United States.

Enrollment
3rd of 25
413 · median 98
Started
2017
the only one that year
Phase 1
3 of 25
none open now
Registered
21st of 25
by date
Lead sponsor
6 of 25
Taro Pharmaceuticals USA

Among the 25 studies in Lice Infestations with a site in United States, this one is the 3rd largest by enrollment, is the only one that started in 2017, is one of 3 in phase 1, and was the 21st registered.

Lice Infestations

43 studies on the registry are indexed under Lice Infestations; 4 are open to participants now.

Browse Lice Infestations studies →

Open to participants now

1 of the 25 studies in Lice Infestations with a site in United States is open now. Recruiting first, the newest first:

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 3 Lice Infestations studies recruiting now, 2 set no upper age limit and 1 stops at 75 or younger; 3 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Lice Infestations with a site in United States, or all of them as a file.
02

Study summary

A Multi-Center, Double-Blind, Randomized, Placebo controlled, Parallel-group study, comparing Ivermectin Lotion, 0.5%

Read the detailed description

A Multi-Center, Double-Blind, Randomized, Placebo controlled, Parallel-group study, comparing Ivermectin Lotion, 0.5% to Sklice (Ivermectin) Lotion, 0.5% and both active treatment to a placebo control in the treatment of subjects with active infestation with head lice and their Ova

03

Conditions studied

  • Lice; Head Lice

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects 18 years of age or older must have provided IRB-approved written and sign a HIPAA authorization.
  • Subjects must be willing and able to understand and comply with the requirements of the protocol, including attendance at the required study visits.

Exclusion criteria

Exclusion Criteria:

  • Subjects with a history of or allergy to or any component of the study product.
  • Subject with history of irritation or sensitivity to pediculicides or hair care products.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
413 participants (actual)

Study arms

  • Experimental
    Ivermectin Lotion, 0.5%

    One 10 minute application, under at-home use conditions

    Drug: Ivermectin Lotion, 0.5%

  • Active comparator
    SKLICE (ivermectin) Lotion, 0.5%

    One 10 minute application, under at-home use conditions

    Drug: SKLICE (ivermectin) Lotion, 0.5%

  • Placebo comparator
    Vehicle of the Test product

    One 10 minute application, under at-home use conditions

    Drug: Vehicle of the Test product

Interventions

  • Ivermectin Lotion, 0.5% (Taro Pharmaceuticals Inc.)

    Also known as: ivermectin

  • SKLICE (ivermectin) Lotion, 0.5% (Arbor Pharmaceuticals, LLC)

    Also known as: ivermectin

  • DrugVehicle of the Test product

    Vehicle for Ivermectin Lotion, 0.5% (Taro Pharmaceuticals Inc.)

    Also known as: placebo

06

What researchers measure

Primary outcomes

  1. Demonstration of Bioequivalence in proportion of index subjects who are lice free

    Demonstration of Bioequivalence in proportion of index subjects who are lice free

    Time frame: Day 15 (14 days after application of study treatment)

07

Study locations

1 site
  • Taro Pharmaceuticals USA Inc.
    Hawthorne, New York 10532, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2017 to primary completion in Jun 2017, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 3, 2017
First posted
Aug 22, 2017
StartActual
Mar 20, 2017
Primary completionActual
Jun 27, 2017
CompletionActual
Aug 18, 2017
Last update
May 18, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 18, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03257943
Responsible party
Sponsor
First posted
Aug 22, 2017
Start date
Mar 20, 2017
Primary completion
Jun 27, 2017
Completion
Aug 18, 2017
Last update
May 18, 2018

Study contacts

Catawba Research
study chair · http://catawbaresearch.com/contact/

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ivermectin

Start the discussion